Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism

[1]  S. Rorive,et al.  Exceptionally long‐term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy , 2014, International journal of cancer.

[2]  D. Williams,et al.  In vitro metabolism of benzo[a]pyrene and dibenzo[def,p]chrysene in rodent and human hepatic microsomes. , 2014, Toxicology letters.

[3]  D. Hu,et al.  Epirubicin Upregulates UDP Glucuronosyltransferase 2B7 Expression in Liver Cancer Cells via the p53 Pathway , 2014, Molecular Pharmacology.

[4]  M. Dimanche-Boitrel,et al.  Protective action of n-3 fatty acids on benzo[a]pyrene-induced apoptosis through the plasma membrane remodeling-dependent NHE1 pathway. , 2014, Chemico-biological interactions.

[5]  V. Arlt,et al.  Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  M. Krstic-Demonacos,et al.  Cytochrome P450 2E1 (CYP2E1) regulates the response to oxidative stress and migration of breast cancer cells , 2013, Breast Cancer Research.

[7]  D. Jerina,et al.  Mutagenicity and tumorigenicity of the four enantiopure bay-region 3,4-diol-1,2-epoxide isomers of dibenz[a,h]anthracene. , 2013, Carcinogenesis.

[8]  Andrew Williams,et al.  Hepatic genotoxicity and toxicogenomic responses in Muta™Mouse males treated with dibenz[a,h]anthracene. , 2013, Mutagenesis.

[9]  Hiba Alogheli,et al.  A Novel p53 Mutant Found in Iatrogenic Urothelial Cancers Is Dysfunctional and Can Be Rescued by a Second-site Global Suppressor Mutation* , 2013, The Journal of Biological Chemistry.

[10]  Shalom Madar,et al.  Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. , 2013, Carcinogenesis.

[11]  David E. Williams,et al.  Polycyclic aromatic hydrocarbons as skin carcinogens: comparison of benzo[a]pyrene, dibenzo[def,p]chrysene and three environmental mixtures in the FVB/N mouse. , 2012, Toxicology and applied pharmacology.

[12]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[13]  Andrew Williams,et al.  Subchronic Oral Exposure to Benzo(a)pyrene Leads to Distinct Transcriptomic Changes in the Lungs That Are Related to Carcinogenesis , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  J. Kucab,et al.  Metabolic activation of diesel exhaust carcinogens in primary and immortalized human TP53 knock‐in (Hupki) mouse embryo fibroblasts , 2012, Environmental and molecular mutagenesis.

[15]  Andrew Williams,et al.  Hepatic mRNA, microRNA, and miR-34a-Target responses in mice after 28 days exposure to doses of benzo(a)pyrene that elicit DNA damage and mutation , 2011, Environmental and molecular mutagenesis.

[16]  P. White,et al.  Simultaneous Measurement of Benzo[a]pyrene-induced Pig-a and lacZ Mutations, Micronuclei and DNA Adducts in Muta™ Mouse , 2011, Environmental and molecular mutagenesis.

[17]  A. Knudson,et al.  A continuum model for tumour suppression , 2011, Nature.

[18]  I. Giddings,et al.  Influence of cell cycle on responses of MCF-7 cells to benzo[a]pyrene , 2011, BMC Genomics.

[19]  C. Prives,et al.  p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation , 2011, Proceedings of the National Academy of Sciences.

[20]  M. Hollstein,et al.  Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform , 2011, Cell cycle.

[21]  V. Arlt,et al.  Aryl hydrocarbon receptor activation during pregnancy, and in adult nulliparous mice, delays the subsequent development of DMBA‐induced mammary tumors , 2011, International journal of cancer.

[22]  Karen H. Vousden,et al.  Metabolic regulation by p53 , 2011, Journal of Molecular Medicine.

[23]  P. Pandolfi,et al.  Haplo‐insufficiency: a driving force in cancer , 2011, The Journal of pathology.

[24]  C. McClain,et al.  Mechanisms and cell signaling in alcoholic liver disease , 2010, Biological chemistry.

[25]  V. Arlt,et al.  Mechanisms of the different DNA adduct forming potentials of the urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone. , 2010, Chemical research in toxicology.

[26]  J. Kucab,et al.  Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock‐in (Hupki) mouse model , 2010, The FEBS journal.

[27]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[28]  S. Burchiel,et al.  Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. , 2010, IARC monographs on the evaluation of carcinogenic risks to humans.

[29]  Alberto Inga,et al.  The expanding universe of p53 targets , 2009, Nature Reviews Cancer.

[30]  K. Kinzler,et al.  A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 , 2009, Proceedings of the National Academy of Sciences.

[31]  Paul D. P. Pharoah,et al.  p53 polymorphisms: cancer implications , 2009, Nature Reviews Cancer.

[32]  V. Arlt,et al.  Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. , 2008, Toxicology and applied pharmacology.

[33]  V. Arlt,et al.  Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo : experiments with Hepatic Cytochrome P450 Reductase Null mice , 2008 .

[34]  I. Giddings,et al.  Identification through microarray gene expression analysis of cellular responses to benzo(a)pyrene and its diol-epoxide that are dependent or independent of p53. , 2008, Carcinogenesis.

[35]  Graham M Lord,et al.  Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. , 2009, Carcinogenesis.

[36]  V. Arlt,et al.  The 32P-postlabeling assay for DNA adducts , 2007, Nature Protocols.

[37]  I. Giddings,et al.  AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines. , 2007, Chemical research in toxicology.

[38]  M. Hollstein,et al.  p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.

[39]  I. Giddings,et al.  Time- and concentration-dependent changes in gene expression induced by benzo(a)pyrene in two human cell lines, MCF-7 and HepG2 , 2006, BMC Genomics.

[40]  J. Milner,et al.  Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency , 2006, Oncogene.

[41]  V. Arlt,et al.  Identification of three major DNA adducts formed by the carcinogenic air pollutant 3‐nitrobenzanthrone in rat lung at the C8 and N2 position of guanine and at the N6 position of adenine , 2006, International journal of cancer.

[42]  K. Brauers,et al.  Development and validation of a modified comet assay to phenotypically assess nucleotide excision repair. , 2006, Mutagenesis.

[43]  J. Ford,et al.  Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. , 2005, Mutation research.

[44]  A. Luch,et al.  Metabolic Activation and Detoxification of Polycyclic Aromatic Hydrocarbons , 2005 .

[45]  B. Sopko,et al.  Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. , 2005, Cancer research.

[46]  B. Mahadevan,et al.  Carcinogenic polycyclic aromatic hydrocarbon‐DNA adducts and mechanism of action , 2005, Environmental and molecular mutagenesis.

[47]  D. Phillips.  Macromolecular adducts as biomarkers of human exposure to polycyclic aromatic hydrocarbons. , 2005 .

[48]  C. Harris,et al.  p53: traffic cop at the crossroads of DNA repair and recombination , 2005, Nature Reviews Molecular Cell Biology.

[49]  A. Ashworth,et al.  Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. , 2004, Biochimica et biophysica acta.

[50]  R. Iggo,et al.  Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[52]  D. Pinkel,et al.  Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation , 1998, The EMBO journal.

[53]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[54]  H. Glatt,et al.  Synthesis and mutagenicity of the diastereomeric fjord-region 11,12-dihydrodiol 13,14-epoxides of dibenzo[a,l]pyrene. , 1994, Carcinogenesis.

[55]  F. Oesch,et al.  Efficient synthesis of non-K-region trans-dihydrodiols of polycyclic aromatic hydrocarbons from o-quinones and catechols , 1983 .

[56]  F. Oesch,et al.  Reductive cyclization of keto acids to polycyclic aromatic hydrocarbons by hydroiodic acid-red phosphorus , 1981 .

[57]  R. Harvey,et al.  Synthesis of biologically active metabolites of dibenz[a,h]anthracene , 1980 .

[58]  D. Jerina,et al.  Synthesis and reactions of the highly mutagenic 7,8-diol 9,10-epoxides of the carcinogen benzo[a]pyrene. , 1977, Journal of the American Chemical Society.

[59]  D. Jerina,et al.  Synthesis of dihydrodiols from chrysene and dibenzo[a,h]anthracene , 1977 .